These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21539403)

  • 1. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
    Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
    Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
    Krishnan SM; Pennick M; Stark JG
    Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
    Krishnan S; Zhang Y
    J Clin Pharmacol; 2008 Mar; 48(3):293-302. PubMed ID: 18285619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
    Ermer J; Corcoran M; Lasseter K; Martin PT
    Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
    Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
    Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
    Krishnan SM; Stark JG
    Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.
    Ermer J; Haffey MB; Richards C; Lasseter K; Roesch B; Purkayastha J; Corcoran M; Harlin B; Martin P
    Clin Drug Investig; 2013 Apr; 33(4):243-54. PubMed ID: 23512639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
    Haffey MB; Buckwalter M; Zhang P; Homolka R; Martin P; Lasseter KC; Ermer JC
    Postgrad Med; 2009 Sep; 121(5):11-9. PubMed ID: 19820270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
    Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
    Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
    Ermer J; Martin P; Corcoran M; Matsuo Y
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
    Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
    Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
    Martin P; Dirks B; Gertsik L; Walling D; Stevenson A; Corcoran M; Raychaudhuri A; Ermer J
    J Clin Psychopharmacol; 2014 Dec; 34(6):682-9. PubMed ID: 25310201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults.
    Ermer J; Haffey MB; Richards C; Lasseter K; Adeyi B; Corcoran M; Stanton B; Martin P
    Neuropsychiatr Dis Treat; 2013; 9():219-29. PubMed ID: 23431065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):410-8. PubMed ID: 18635707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.